Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alb-IFN plus ribavirin versus peginterferon alfa-2a plus ribavirin for treatment-naive chronic hepatitis C genotype 2/3
ACTRN12607000092493Phase 3Not yet recruiting
- Sponsor
- Human Genome Sciences
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of albinterferon alfa-2b, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (3 arms), sponsored by Human Genome Sciences. Primary endpoint: Sustained virologic response. Planned start Jan 2007; status: not yet recruiting.
02
Drugs
albinterferon alfa-2bpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12607000092493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000092493.